NCT06907875View on ClinicalTrials.gov

A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 8, 2025

Primary Completion Date

March 31, 2031

Study Completion Date

April 30, 2032

Conditions
Facioscapulohumeral Muscular Dystrophy
Interventions
BIOLOGICAL

EPI-321

EPI-321 IV Infusion

Trial Locations (5)

2050

NOT_YET_RECRUITING

Royal Alfred Hospital, Sydney

90095

NOT_YET_RECRUITING

David Geffen School of Medicine at University of California, Los Angeles, Los Angeles

303329

RECRUITING

Rare Disease Research, Atlanta

01605

NOT_YET_RECRUITING

University of Massachusetts Chan Medical School, Worcester

0622

RECRUITING

Pacific Clinical Research Network, Auckland

Sponsors
All Listed Sponsors
lead

Epicrispr Biotechnologies, Inc.

INDUSTRY